indazoles has been researched along with quinazolines in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.56) | 18.2507 |
| 2000's | 15 (19.23) | 29.6817 |
| 2010's | 57 (73.08) | 24.3611 |
| 2020's | 4 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| El-Ablak, FZ; Etman, HA; Metwally, MA | 1 |
| Daidone, G; Maggio, B; Plescia, F; Raffa, D; Schillaci, D | 1 |
| Devaiah, V; Kamal, A; Rao, MV; Reddy, KL; Shankaraiah, N | 1 |
| Teng, CM; Wu, CC | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Kibble, A | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Di Serio, C; Pellerito, S; Tarantini, F | 1 |
| Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L | 1 |
| Sherman, SI | 2 |
| Bukowski, RM; Vakkalanka, BK | 1 |
| Döme, B; Magyar, M | 1 |
| Hilgeroth, A; Krug, M | 1 |
| Belvin, M; Eastham-Anderson, J; Friedman, LS; Gunter, B; Haverty, PM; Hoeflich, KP; Lee-Hoeflich, ST; Lewin-Koh, N; Murray, LJ; Sliwkowski, MX; Truong, T; Yao, E; Zhou, W | 1 |
| Commo, F; Dessen, P; Kroemer, G; Lacroix, L; Lazar, V; Olaussen, KA; Raza, SQ; Richon, C; Soria, JC; Tailler, M; Vitale, I | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Fischer, MJ | 1 |
| Krchnák, V; Krupková, S; Slough, GA | 1 |
| Alber, JA; Ding, J; Mas Lopez, L; Monk, BJ; Oaknin, A; Pandite, LN; Stutts, MW; Tarpin, C; Termrungruanglert, W; Zarba, JJ | 1 |
| Kiyoi, H | 1 |
| Ghazaly, E; Joel, S; Kitromilidou, C; McGrowder, EH; Perry, J; Powles, T | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Goozner, M | 1 |
| Döme, B; Török, S | 1 |
| Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Arumugham, T; de Jonge, MJ; Hamberg, P; Hodge, J; Hurwitz, HI; Pandite, LN; Savage, S; Suttle, AB; Verweij, J | 1 |
| Adjei, AA; Burris, HA; Dy, GK; Eckhardt, SG; Huff, A; Infante, JR; Jones, SF; Ma, WW; Novello, S; Ottesen, LH; Suttle, AB; Wang, Q | 1 |
| Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM | 1 |
| Alvarez, RH; Blackwell, KL; Cristofanilli, M; Gladkov, O; Gomez, HL; Johnston, SR; Manikhas, A; Ranganathan, S; Redhu, S; Rubin, SD; Safina, S; Shao, Z; Trudeau, ME | 1 |
| Durante, M; Gómez, H; Goodman, V; Johnston, SR; Pandite, L; Richie, M; Slamon, D; Stemmer, SM | 1 |
| Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY | 1 |
| Hunt, CM; Spraggs, CF; Xu, CF | 1 |
| Robert, C; Sibaud, V | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Alam, S; Gupta, A; Maurya, HK; Negi, AS; Pandey, S; Pathak, V; Sharma, S; Srivastava, KK; Verma, R | 1 |
| Dixon, SJ; Jirik, FR; Kashishian, A; Lannutti, BJ; Pereverzev, A; Puri, KD; Shugg, RP; Sims, SM; Steiner, BH; Tanabe, N; Thomson, A | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Cao, B; Hou, T; Li, D; Li, Y; Mao, X; Pan, P; Wang, M; Zhu, J | 1 |
| Ando, Y; Araki, K; Inada-Inoue, M; Ishida, H; Kawada, K; Mitsuma, A; Mizuno, K; Nagamatsu, K; Nagashima, F; Sasaki, Y; Sawaki, M; Sunakawa, Y; Takekura, A; Yamashita, K; Yokoyama, T | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Kisseljova, K; Krchňák, V; Smyslová, P | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Fu, S; George, GC; Henary, H; Hong, DS; Kurzrock, R; Mistry, R; Naing, A; Piha-Paul, S; Wheler, J; Zinner, R | 1 |
| Covell, LL; Ganti, AK | 1 |
| Ishii, K; Mori, A; Nakahara, T; Nakano, A; Sakamoto, K; Ushikubo, H | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Crijns, HJ; De Boer, HC; De Jong, AM; Kamphuisen, PW; Kuiper, M; Lau, DH; Linz, D; Lumeij, S; Maass, AH; Rienstra, M; Schotten, U; Spronk, HM; Ten Cate, H; Van Gelder, IC; van Hunnik, A; van Zonneveld, AJ; Verheule, S; Zeemering, S | 1 |
| Carter, JJ; Fretwell, LV; Woolard, J | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Craveiro, RB; Dilloo, D; Ehrhardt, M; Goetz, B; Olschewski, M; Pietsch, T; Velz, J | 1 |
| Albiol-Chiva, J; Esteve-Romero, J; Peris-Vicente, J | 1 |
| Chatterjee, AK; Cheng, B; Franzblau, SG; Guo, H; Harbut, MB; Jacobs, WR; Liu, R; Lockner, J; Petrassi, HM; Rubin, H; Vilchèze, C; Wang, F; Yang, B; Yano, T; Yu, C | 1 |
| Bednarikova, Z; Gancar, M; Gazova, Z; Hu, CK; Li, MS; Linh, HQ; Thai, NQ | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Agnihotri, VK; Ansari, AJ; Chandaluri, CG; Joshi, G; Kumar, R; Maurya, AK; Metre, RK; Sawant, DM; Sharma, P; Singh, S | 1 |
| Abdel-Aziz, HA; Abdelsalam, EA; Abou Taleb, NA; Amin, KM; Eldehna, WM; Hammad, SF; Mekawey, AAI; Zaghary, WA | 1 |
| Carter, JJ; Cooper, SL; March, J; Woolard, J | 1 |
| Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X | 1 |
| Khan, T; Prabhu, A; Sankhe, K | 1 |
| Chen, S; Lensing, MM; Lyu, C; Wagner, KU; Weigel, RJ; Ye, Y | 1 |
| Dherange, BD; Hyland, EE; Kelly, PQ; Levin, MD; McKillop, AM | 1 |
30 review(s) available for indazoles and quinazolines
| Article | Year |
|---|---|
Recent advances in the solid-phase combinatorial synthetic strategies for the quinoxaline, quinazoline and benzimidazole based privileged structures.
Topics: Benzimidazoles; Benzothiadiazines; Combinatorial Chemistry Techniques; Heterocyclic Compounds, 2-Ring; Indazoles; Molecular Structure; Phthalazines; Pyrans; Quinazolines; Quinoxalines | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Recent advances in the development of multi-kinase inhibitors.
Topics: Animals; Benzamides; Carbanilides; Humans; Indazoles; Indoles; Phthalazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Quinazolines | 2008 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Calcitonin gene-related peptide receptor antagonists for migraine.
Topics: Animals; Azepines; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Clinical Trials as Topic; Dipeptides; Humans; Imidazoles; Indazoles; Migraine Disorders; Piperazines; Quinazolines; Quinazolinones; Treatment Outcome; Trigeminal Nerve | 2010 |
[FLT3 kinase inhibitors for the treatment of acute leukemia].
Topics: Acute Disease; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia; Mutation; Piperazines; Quinazolines; Signal Transduction; Staurosporine | 2010 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
Topics: Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Gilbert Disease; Glucuronosyltransferase; Humans; Indazoles; Lapatinib; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2021 |
Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Azepines; Benzamides; Drug Approval; Drug Resistance; Drug Screening Assays, Antitumor; Flavones; Gene Expression Regulation; Humans; Indazoles; Neoplasms; Organophosphates; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2021 |
10 trial(s) available for indazoles and quinazolines
| Article | Year |
|---|---|
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indazoles; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Retreatment; Sulfonamides; Uterine Cervical Neoplasms | 2010 |
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides; Young Adult | 2013 |
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Demography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Quinazolines; Sulfonamides; Treatment Outcome | 2013 |
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Female; Humans; Indazoles; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Humans; Indazoles; Lapatinib; Middle Aged; Neoplasm Staging; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lapatinib; Male; Middle Aged; Neoplasms; Pyrimidines; Quinazolines; Sulfonamides | 2014 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Indazoles; Lapatinib; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides | 2015 |
38 other study(ies) available for indazoles and quinazolines
| Article | Year |
|---|---|
Synthesis and antimicrobial activity of some new carbazoles, indazoles, quinolines, quinazolines and naphthalenes from 3-methyl-5-phenyl-6-benzylidene-2-cyclohexene-1-one.
Topics: Anti-Bacterial Agents; Bacteria; Carbazoles; Indazoles; Microbial Sensitivity Tests; Naphthalenes; Quinazolines; Quinolines | 1995 |
Synthesis and antiproliferative activity of novel 3-(indazol-3-yl)-quinazolin-4(3H)-one and 3-(indazol-3-yl)-benzotriazin-4(3H)-one derivatives.
Topics: Antineoplastic Agents; Chemical Phenomena; Chemistry, Physical; Humans; Indazoles; Magnetic Resonance Spectroscopy; Quinazolines; Triazines; Tumor Cells, Cultured | 1999 |
Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Topics: Blood Platelets; Crotalid Venoms; Dose-Response Relationship, Drug; Drug Synergism; Humans; In Vitro Techniques; Indazoles; Oligopeptides; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Thrombin; Thrombin; Urea | 2006 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Comments on "Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis".
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line; Cell Proliferation; Chick Embryo; Endothelial Cells; Humans; Indazoles; Neovascularization, Physiologic; Pyrroles; Quinazolines; Receptor, PAR-1; Urea | 2008 |
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Enzyme Inhibitors; Humans; Indazoles; Lapatinib; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Taxoids; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Indazoles; Lapatinib; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2009 |
Synthesis of quinazolines from N-(2-nitrophenylsulfonyl)iminodiacetate and alpha-(2-nitrophenylsulfonyl)amino ketones via 2H-indazole 1-oxides.
Topics: Benzenesulfonamides; Catalysis; Imino Acids; Indazoles; Ketones; Molecular Structure; Nitrophenols; Oxides; Quinazolines; Sulfonamides | 2010 |
A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Cycle; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Humans; Indazoles; Intracellular Space; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2010 |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured | 2011 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line; Dogs; Erlotinib Hydrochloride; Indazoles; Male; Mice; Morpholines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2012 |
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Studies on substituted benzo[h]quinazolines, benzo[g]indazoles, pyrazoles, 2,6-diarylpyridines as anti-tubercular agents.
Topics: Antitubercular Agents; Cell Line; Humans; Indazoles; Mycobacterium tuberculosis; Pyrazoles; Pyridines; Quinazolines; Tuberculosis | 2013 |
Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.
Topics: Adenine; Androstadienes; Animals; Bone Resorption; Cell Survival; Chromones; Cytoskeleton; Indazoles; Isoenzymes; Morpholines; Osteoclasts; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Rabbits; RANK Ligand; Rats; Sulfonamides; Wortmannin | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Topics: Adenine; Binding Sites; Enzyme Inhibitors; Hydrogen Bonding; Indazoles; Models, Molecular; Molecular Conformation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Conformation; Protein Isoforms; Quinazolines; Sulfonamides | 2014 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
Benzhydrylamines via base-mediated intramolecular sp(3) C-arylation of N-benzyl-2-nitrobenzenesulfonamides--advanced intermediates for the synthesis of nitrogenous heterocycles.
Topics: Alcohols; Benzhydryl Compounds; Benzyl Compounds; Heterocyclic Compounds; Indazoles; Indicators and Reagents; Quinazolines | 2014 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
Short-term treatment with VEGF receptor inhibitors induces retinopathy of prematurity-like abnormal vascular growth in neonatal rats.
Topics: Animals; Animals, Newborn; Axitinib; Disease Models, Animal; Female; Fluorescent Antibody Technique, Indirect; Imidazoles; Indazoles; Microscopy, Fluorescence; Phenylurea Compounds; Pregnancy; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Sprague-Dawley; Retinal Neovascularization; Retinal Vessels; Retinopathy of Prematurity; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; Female; Fibrinolytic Agents; Fibroblasts; Fibrosis; Goats; Heart Atria; Indazoles; Mice, Transgenic; Nadroparin; Peptide Hydrolases; Pyrroles; Quinazolines; Rats; Receptors, Thrombin; Thrombin; Thrombophilia; Urea | 2017 |
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides | 2017 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Indazoles; Medulloblastoma; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides | 2017 |
Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines.
Topics: Afatinib; Antineoplastic Agents; Axitinib; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Indazoles; Lapatinib; Limit of Detection; Linear Models; Micelles; Neoplasms; Quinazolines; Reproducibility of Results | 2018 |
Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity.
Topics: Anti-Bacterial Agents; Drug Evaluation, Preclinical; Indazoles; Microbial Viability; Mycobacterium tuberculosis; NADH Dehydrogenase; Quinazolines | 2018 |
Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Computer Simulation; Humans; In Vitro Techniques; Indazoles; Molecular Dynamics Simulation; Peptide Fragments; Pyridines; Quinazolines | 2018 |
Pd-Catalyzed Four-Component Sequential Reaction Delivers a Modular Fluorophore Platform for Cell Imaging.
Topics: Amines; Catalysis; Cell Line, Tumor; Cytological Techniques; Cytoplasm; Fluorescent Dyes; Humans; Indazoles; Mitochondria; Palladium; Quinazolines; Staining and Labeling | 2019 |
Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship | 2019 |
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Topics: Animals; Arterial Pressure; Disease Models, Animal; Drug Administration Schedule; Humans; Hypertension; Indazoles; Male; Piperidines; Pyrimidines; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides | 2019 |
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Topics: Animals; Antineoplastic Agents, Immunological; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelium; ErbB Receptors; Female; Humans; Indazoles; Lapatinib; Mammary Glands, Animal; Mice, Transgenic; Neoplasm Metastasis; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Signal Transduction; Sulfonamides; Trastuzumab; Up-Regulation | 2021 |
Unified Access to Pyrimidines and Quinazolines Enabled by N-N Cleaving Carbon Atom Insertion.
Topics: Carbon; Indazoles; Pyrimidines; Quinazolines; Rosuvastatin Calcium | 2022 |